PO-03-075 RISK OF CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICE INFECTION IN PATIENTS WITH CARDIAC SARCOIDOSIS

Immunosuppression is an essential aspect of managing cardiac sarcoidosis (CS). The decision to implant a cardiovascular implantable electronic device (CIED) often made in conjunction with starting immunosuppression. It unclear if immunosuppression at the time implantation increases risk CIED infections. Since both are potentially life-saving therapies for CS, it vital understand there need adjust immunosuppressive regimen before implanting CIEDs reduce infection risk. To evaluate rate infections patients tertiary hospital. We performed retrospective analysis biopsy-proven CS and history who had received care Johns Hopkins Hospital. For each patient, we compiled information on type CIED, number procedures leads, presence antibiotic envelope, procedure. primary outcome was pocket or bloodstream (BSI). Of 175 included, average age 60.1 years (SD=11.4), 111/175 (63.4%) were male, 93/175 (53.1%) White 72/175 (41.1%) Black. Most cardioverter-defibrillators (ICD) (162/175, 92.5%). follow-up post-CIED 8.6 years. At implantation, 70/175 immunosuppression: 36 corticosteroid monotherapy, 8 steroid-sparing agent alone, 26 combination both. During study period, 12/175 documented BSIs, occurring 5 post-implant. Five 12 implantation. All treated antibiotics 9/12 extractions. There no significant difference among those vs off (5/70 7/105 p=0.90). Two BSIs also infection, context multiple prior procedures. One patient dual chamber ICD developing S. aureus 4 after revision A second single 3 P. acnes months Among undergoing implant, found significantly increased implant.